GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
This article was originally published in PharmAsia News
Executive Summary
Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.
You may also be interested in...
GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.
GSK Bundles Legacy Drugs Into Separate Portfolio In Housekeeping Move
GlaxoSmithKline is bundling around 50 legacy drugs comprising some £3 billion ($4.6 billion) in annual sales into a standalone global portfolio, in a “housekeeping” move that Britain’s biggest medicines maker says is needed to better prepare the group for its coming wave of new product launches.
Sales & Earnings In Brief
Sanofi now world’s No. 3 OTC player; Glaxo weighs Lucozade energy drink divestment; NBTY wraps Balance Bar integration; Vicks launches in Europe boost Teva OTC business; flu trend breeds cautious optimism for Prestige Brands; USANA and Nu Skin face tough times for multilevel marketers.